Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion
Keay Nakae

Keay Nakae Analyst Performance

Senior Research Analyst, Small RNA, Microbiome, Digital Therapeutics at Chardan Capital

Keay Nakae is a stock analyst at Chardan Capital focused in the medical sector, covering 36 publicly traded companies. Over the past year, Keay Nakae has issued 66 stock ratings, including buy and hold recommendations. While full access to Keay Nakae's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Keay Nakae's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
179 Last 10 Years
Buy Recommendations
92.05% 162 Buy Ratings
Companies Covered
36 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy92.0%162 ratings
Hold7.4%13 ratings
Sell0.6%1 ratings

Out of 176 total stock ratings issued by Keay Nakae at Chardan Capital, the majority (92.0%) have been Buy recommendations, followed by 7.4% Hold and 0.6% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
88.9% of companies on NASDAQ
32 companies
NYSE
8.3% of companies on NYSE
3 companies
NYSEAMERICAN
2.8% of companies on NYSEAMERICAN
1 company

Keay Nakae, an analyst at Chardan Capital, currently covers 36 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
35 companies
97.2%
Manufacturing
1 company
2.8%

Keay Nakae of Chardan Capital specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
21 companies
58.3%
MED - DRUGS
5 companies
13.9%
PHARMACEUTICAL PREPARATIONS
4 companies
11.1%
MED PRODUCTS
2 companies
5.6%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
2.8%
BIOTECHNOLOGY
1 company
2.8%
MEDICAL SERVICES
1 company
2.8%
MED INSTRUMENTS
1 company
2.8%

About Keay Nakae

Keay Nakae is a Senior Research Analyst at Chardan. Mr. Nakae has over 17 years of experience as a sell-side research analyst covering healthcare companies, and has previously worked at Wedbush Morgan, and CE Unterberg Towbin/Collins Stewart. Mr. Nakae has made numerous media appearances on Bloomberg TV, and has been quoted in publications such as The Wall Street Journal, Time, Business Week, and The Los Angeles Times. He has been recognized by Forbes magazine in its annual survey of America’s Best Analysts. Mr. Nakae earned an MBA degree from UCLA’s Anderson School of Management, and holds MS and BS degrees in electronic engineering from Cal Poly. Mr. Nakae is a CFA charterholder and a member of the CFA Institute.
Follow on LinkedIn

Keay Nakae's Ratings History at Chardan Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/22/2026Reiterated Rating$27.13$30.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
4/9/2026Reiterated Rating$1.83$4.00Buy
iBio, Inc. stock logo
IBIO
iBio
4/9/2026Reiterated Rating$2.24$5.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/2/2026Reiterated Rating$23.38$30.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
3/30/2026Reiterated Rating$54.10$100.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
3/25/2026Reiterated Rating$326.30$425.00Buy
iBio, Inc. stock logo
IBIO
iBio
3/18/2026Reiterated Rating$2.46$5.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3/18/2026Reiterated Rating$32.87$35.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
3/17/2026Reiterated Rating$24.27$30.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
3/16/2026Reiterated Rating$4.47$14.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
3/12/2026Reiterated Rating$4.38$20.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
3/11/2026Boost Price Target$4.54$14.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3/9/2026Reiterated Rating$17.64$38.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3/2/2026Reiterated Rating$16.15$38.00Buy
Allurion Technologies, Inc. stock logo
ALUR
Allurion Technologies
2/24/2026Set Price Target$1.75$3.00Buy
Allurion Technologies, Inc. stock logo
ALUR
Allurion Technologies
2/24/2026Set Price Target$1.22$3.00
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2/13/2026Lower Price Target$308.48$425.00Buy
iBio, Inc. stock logo
IBIO
iBio
2/12/2026Reiterated Rating$2.21$5.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
1/29/2026Upgrade$11.69$15.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1/29/2026Reiterated Rating$67.43$100.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
1/8/2026Reiterated Rating$5.12$14.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1/7/2026Boost Price Target$70.81$80.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
1/5/2026Set Price Target$30.90$35.00
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
1/5/2026Reiterated Rating$6.20$40.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
1/5/2026Boost Price Target$30.90$35.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
1/5/2026Boost Price Target$16.61$30.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
12/18/2025Reiterated Rating$3.96$12.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
12/9/2025Reiterated Rating$22.20$38.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
12/1/2025Reiterated Rating$52.78$60.00Buy
Allurion Technologies, Inc. stock logo
ALUR
Allurion Technologies
11/20/2025Reiterated Rating$1.35Neutral
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
11/19/2025Reiterated Rating$40.47$60.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
11/17/2025Reiterated Rating$3.24$12.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
11/14/2025Reiterated Rating$5.96$14.00Buy
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
11/14/2025Reiterated Rating$4.52$5.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
11/13/2025Reiterated Rating$31.42Neutral
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
11/13/2025Reiterated Rating$4.42$20.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
11/11/2025Reiterated Rating$69.84$72.00Neutral
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
11/9/2025Boost Price Target$80.95$100.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
11/4/2025Reiterated Rating$2.59$4.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
10/28/2025Reiterated Rating$70.00$72.00Neutral
From the man who predicted 2008 crash… (Ad)

Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Watch Porter Stansberry's full briefing and learn how to prepare now
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
10/28/2025Set Price Target$70.00$72.00
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
10/28/2025Downgrade$69.93$72.00Hold
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
9/25/2025Boost Price Target$73.04$85.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
9/19/2025Reiterated Rating$2.38$12.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
9/17/2025Reiterated Rating$5.67$14.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
9/16/2025Reiterated Rating$54.49$60.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
9/10/2025Reiterated Rating$47.34$75.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
8/13/2025Reiterated Rating$6.02$14.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
8/13/2025Reiterated Rating$18.93$25.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
8/13/2025Reiterated Rating$33.51$60.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
8/13/2025Reiterated Rating$2.66$20.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
8/11/2025Reiterated Rating$16.42$60.00Buy
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
8/11/2025Reiterated Rating$3.40$5.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
8/8/2025Lower Price Target$2.23$12.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
8/8/2025Reiterated Rating$5.38$35.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8/8/2025Reiterated Rating$2.05$4.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
8/8/2025Reiterated Rating$47.52$75.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
8/7/2025Reiterated Rating$2.64$20.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8/1/2025Boost Price Target$392.24$400.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
7/29/2025Lower Price Target$9.31$38.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
7/1/2025Reiterated Rating$5.72$14.00Buy
iBio, Inc. stock logo
IBIO
iBio
6/25/2025Reiterated Rating$0.75$5.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
6/23/2025Initiated Coverage$32.86$60.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
6/17/2025Reiterated Rating$11.48$50.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
6/13/2025Reiterated Rating$5.59$35.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
6/9/2025Boost Price Target$33.13$75.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
5/15/2025Reiterated Rating$2.01$20.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
5/13/2025Reiterated Rating$13.97$60.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
5/13/2025Reiterated Rating$2.94$20.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
5/13/2025Reiterated Rating$5.76$14.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
5/9/2025Reiterated Rating$11.32$50.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
5/9/2025Lower Price Target$3.56$35.00Buy
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
5/8/2025Reiterated Rating$8.29$6.00Neutral
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
5/7/2025Reiterated Rating$26.26$65.00Buy
iBio, Inc. stock logo
IBIO
iBio
5/5/2025Reiterated Rating$1.01$5.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
5/2/2025Boost Price Target$255.13$325.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
4/28/2025Reiterated Rating$6.18$14.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
4/22/2025Reiterated Rating$2.90$20.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
4/16/2025Initiated Coverage$13.40$25.00Buy
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
4/7/2025Reiterated Rating$1.25$20.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
4/1/2025Lower Price Target$1.40$20.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
4/1/2025Reiterated Rating$3.24$20.00Buy
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3/28/2025Reiterated Rating$2.07$6.00Buy
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
3/28/2025Reiterated Rating$3.27$5.00Buy
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
3/28/2025Reiterated Rating$1.31$20.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
3/21/2025Reiterated Rating$253.60$300.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
3/20/2025Reiterated Rating$6.45$14.00Buy
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3/20/2025Reiterated Rating$14.64$25.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3/17/2025Reiterated Rating$12.22$50.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3/14/2025Reiterated Rating$1.74$4.00Buy
The chokepoint supplier behind SpaceX's $1.75 trillion empire (Ad)

When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.tc pixel

See the stock Musk's own words pointed to right here
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2/28/2025Reiterated Rating$13.30$50.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2/26/2025Reiterated Rating$245.20$300.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2/11/2025Reiterated Rating$19.92$60.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
2/6/2025Reiterated Rating$7.00$14.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
1/29/2025Reiterated Rating$2.28$25.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
1/10/2025Reiterated Rating$15.46$50.00Buy